基本數據
| CIK | 1832038 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Adagio Therapeutics Inc
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| May 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2026 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2026 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 14, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Invivyd, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.0001 par value per share Other 14,099,351 $ 1.47 $ 20,726,045.97 0.0001381 $ 2,862.27 2 Equity Common |
|
| May 14, 2026 |
As filed with the Securities and Exchange Commission on May 14, 2026 As filed with the Securities and Exchange Commission on May 14, 2026 Registration No. |
|
| May 14, 2026 |
AMENDMENT NO. 1 TO THE SECOND AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AGREEMENT Exhibit 10.6 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONFIDENTIAL AMENDMENT NO. 1 TO THE SECOND AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AGREEMENT THIS AMENDMENT NO. 1 TO THE SECOND AMENDED AND RESTATED CO |
|
| May 14, 2026 |
AMENDMENT NO. 3 TO THE CELL LINE LICENSE AGREEMENT Exhibit 10.7 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONFIDENTIAL AMENDMENT NO. 3 TO THE CELL LINE LICENSE AGREEMENT THIS AMENDMENT NO. 3 TO THE CELL LINE LICENSE AGREEMENT (this “Amendment No. 3”), effective as of Marc |
|
| May 14, 2026 |
AMENDMENT NO. 1 TO THE MASTER SERVICES AGREEMENT Exhibit 10.8 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONFIDENTIAL AMENDMENT NO. 1 TO THE MASTER SERVICES AGREEMENT THIS AMENDMENT NO. 1 TO THE MASTER SERVICES AGREEMENT (this “Amendment No. 1”), effective as of March 4, |
|
| May 14, 2026 |
EX-99.1 Exhibit 99.1 Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million • Invivyd in vitro data showed continued neutralizing activity of pemivibart and VYD2311 against SARS-CoV-2 variant BA.3.2.2 (“Cicada”), co |
|
| May 14, 2026 |
EX-99.2 Exhibit 99.2 Q1 2026 Earnings Call & Business Update May 14, 2026 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “sh |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, |
|
| April 9, 2026 |
EX-99.2 Exhibit 99.2 REVOLUTION Program & Measles April 9, 2026 © 2026 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are |
|
| April 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 9, 2026 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 9, 2026 |
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and EX-99.1 Exhibit 99.1 Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles • Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical p |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) շ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ն TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. ( |
|
| April 6, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 5, 2026 |
Exhibit 10.16 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF TIMOTHY LEE This First Amendment to the Employment Agreement of Timothy Lee (the “Amendment”) is entered into this January 31, 2026 (the “Amendment Effective Date”), by and between Timothy Lee (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and Executive have entered into that certain Employment Agreeme |
|
| March 5, 2026 |
Exhibit 10.7 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF JILL ANDERSEN This First Amendment to the Employment Agreement of Jill Andersen (the “Amendment”) is entered into this January 31, 2026 (the “Amendment Effective Date”), by and between Jill Andersen (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and Executive have entered into that certain Employment Ag |
|
| March 5, 2026 |
Exhibit 10.14 SECOND AMENDMENT TO THE EMPLOYMENT AGREEMENT OF JULIE GREEN This Second Amendment to the Employment Agreement of Julie Green (the “Amendment”) is entered into this January 31, 2026 (the “Amendment Effective Date”), by and between Julie Green (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and Executive have entered into that certain Employment Agree |
|
| March 5, 2026 |
Exhibit 19.1 INSIDER TRADING PREVENTION POLICY 1.0 POLICY It is the policy of Invivyd, Inc. and its subsidiaries (“Invivyd”) to prohibit insider trading, i.e., the purchase or sale of a company’s securities by anyone who is aware of Material Non-Public Information (as defined below) about that company. Taking advantage of this privileged information is considered a breach of the individual’s fiduc |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2026 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 5, 2026 |
EX-99.2 Exhibit 99.2 Invivyd Q4 Earnings Call & Business Update March 5, 2026 © 2026 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presen |
|
| March 5, 2026 |
EX-99.1 Exhibit 99.1 Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates • Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter • 2025 year-end cash and cash equivalents of $226.7 million after raising ove |
|
| March 5, 2026 |
Exhibit 10.9 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF ROBERT ALLEN This First Amendment to the Employment Agreement of Robert Allen (the “Amendment”) is entered into this January 31, 2026 (the “Amendment Effective Date”), by and between Robert Allen (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and Executive have entered into that certain Employment Agree |
|
| March 5, 2026 |
INVIVYD, INC. 2026 INDUCEMENT PLAN Exhibit 10.4 INVIVYD, INC. 2026 INDUCEMENT PLAN 1. GENERAL. (a) Plan Purpose. The Plan, through the granting of Awards, is intended to provide (i) an inducement material for certain individuals to enter into employment with the Company or its Affiliates within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules, as applicable, and the related guidance under Nasdaq IM 5635-1 (and any analogo |
|
| March 5, 2026 |
Exhibit 10.2 INVIVYD, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 27, 2021 APPROVED BY THE STOCKHOLDERS: JULY 29, 2021 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve |
|
| March 5, 2026 |
Exhibit 10.11 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF WILLIAM DUKE This First Amendment to the Employment Agreement of William Duke (the “Amendment”) is entered into this January 31, 2026 (the “Amendment Effective Date”), by and between William Duke (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and Executive have entered into that certain Employment Agre |
|
| March 5, 2026 |
INVIVYD, INC. INDEMNIFICATION AGREEMENT Exhibit 10.5 INVIVYD, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , 20, and is between Invivyd, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporations or in certain other cap |
|
| March 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. ( |
|
| March 5, 2026 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Invivyd, Inc. (the “Company”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is the Company’s common |
|
| March 5, 2026 |
Exhibit 21.1 Invivyd, Inc. Subsidiaries Subsidiary Jurisdiction of Incorporation Invivyd Security Corporation Massachusetts Invivyd Netherlands B.V. The Netherlands |
|
| January 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2026 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 8, 2026 |
01 Invivyd Approach 02 COVID 03 Long COVID agenda 04 RSV 05 Financial Highlights 3 EX-99.2 Exhibit 99.2 Invivyd Corporate Deck January 2026 © 2026 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not s |
|
| January 8, 2026 |
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights EX-99.1 Exhibit 99.1 Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights • Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter • Preliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2 |
|
| December 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 23, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 23, 2025 |
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID Exhibit 99.1 Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID NEW HAVEN, Conn., Dec. 23, 2025 – Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational vaccine-alternative monoclonal antibody candidate for the prevention of COVID. Fast Track is a |
|
| December 19, 2025 |
Calculation of Filing Fee Tables S-3 Invivyd, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec |
|
| December 19, 2025 |
As filed with the Securities and Exchange Commission on December 19, 2025 S-3/A As filed with the Securities and Exchange Commission on December 19, 2025 Registration No. |
|
| November 24, 2025 |
Exhibit 99.1 Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness • VBY329 is designed for the prevention of Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children, and results from Invivyd’s proprietary antibody discovery technology platform • VBY329 meets Invivyd’s target profile of higher potency and impro |
|
| November 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 24, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 19, 2025 |
Invivyd Announces Proposed Public Offering of Common Stock Exhibit 99.1 Invivyd Announces Proposed Public Offering of Common Stock NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) - Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the share |
|
| November 19, 2025 |
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants Exhibit 99.2 Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) – Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an offering price of $2.50 per share and, to certain investors, in lieu of common stock, pre |
|
| November 19, 2025 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 Final Form FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2025 Invivyd, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), is entitl |
|
| November 19, 2025 |
Calculation of Filing Fee Tables S-3 Invivyd, Inc. Table 1: Newly Registered and Carry Forward Securities ☑Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 19, 2025 |
Exhibit 1.1 Invivyd, Inc. 44,000,000 Shares of Common Stock (par value $0.0001 per share) Pre-Funded Warrants to Purchase 6,000,000 Shares of Common Stock Underwriting Agreement November 17, 2025 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 110 East 59th Street, 6th Floor New York, NY 10022 Ladies and Gentlemen: Inviv |
|
| November 19, 2025 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267643 PROSPECTUS SUPPLEMENT (To Prospectus dated October 5, 2022) 44,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 6,000,000 Shares of Common Stock We are offering 44,000,000 shares of our common stock, par value $0.0001 per share, and, in lieu of common stock to certain investors that so choose, |
|
| November 17, 2025 |
Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock FWP Issuer Free Writing Prospectus dated November 17, 2025 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration Statement No. |
|
| November 17, 2025 |
SUBJECT TO COMPLETION, DATED NOVEMBER 17, 2025 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| November 6, 2025 |
EX-99.2 Exhibit 99.2 Invivyd Q3 Earnings Call & Business Update November 6, 2025 © 2025 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this pre |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIV |
|
| November 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 6, 2025 |
EX-99.1 Exhibit 99.1 Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights • PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth quarter-over-quarter • October 2025 ending cash and cash equivalents of over $100 million; ended Q3 2025 with $85.0 million in cash and cash equivalents afte |
|
| October 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 30, 2025 |
EX-99.1 Life can only be understood backwards; but it must be lived forwards… KIERKEGAARD Invivyd 1 October 30, 2025 © 2025 Invivyd, Inc. All trademarks used in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This historical presentation fact are contains forward forward -looking- looking statements statements . Words within such |
|
| October 6, 2025 |
Exhibit 99.1 Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID • The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025; top-line data anticipated |
|
| October 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 2, 2025 |
EX-4.4 Exhibit 4.4 INDENTURE DATED AS OF , 20 BETWEEN INVIVYD, INC. as Issuer, AND as Trustee Providing for Issuance of Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04 Acts of Holder |
|
| October 2, 2025 |
As filed with the Securities and Exchange Commission on October 2, 2025 S-3 Table of Contents As filed with the Securities and Exchange Commission on October 2, 2025 Registration No. |
|
| October 2, 2025 |
Calculation of Filing Fee Tables S-3 Invivyd, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec |
|
| September 24, 2025 |
INVIVYD APPOINTS PAUL B. BOLNO, M.D. TO ITS BOARD OF DIRECTORS Exhibit 99.1 INVIVYD APPOINTS PAUL B. BOLNO, M.D. TO ITS BOARD OF DIRECTORS NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) - Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served i |
|
| September 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 22, 2025 |
Exhibit 1.1 Invivyd, Inc. 74,811,404 Shares of Common Stock (par value $0.0001 per share) Pre-Funded Warrants to Purchase 21,342,442 Shares of Common Stock Underwriting Agreement August 20, 2025 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 110 East 59th Street, 6th Floor New York, NY 10022 Ladies and Gentlemen: Invivy |
|
| August 22, 2025 |
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants Exhibit 99.2 Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants WALTHAM, Mass., August 20, 2025 (GLOBE NEWSWIRE) – Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at an offering price of $0.52 per share and, to certain investors, in lieu of common stock, pre- |
|
| August 22, 2025 |
424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-267643 PROSPECTUS SUPPLEMENT (To Prospectus dated October 5, 2022) 74,811,404 Shares of Common Stock Pre-Funded Warrants to Purchase up to 21,342,442 Shares of Common Stock We are offering 74,811,404 shares of our common stock, par value $0.0001 per share, and, in lieu of common stock to certain investors that so choose, pre-funded warra |
|
| August 22, 2025 |
Calculation of Filing Fee Tables S-3 Invivyd, Inc. Table 1: Newly Registered and Carry Forward Securities ☑Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec |
|
| August 22, 2025 |
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Exhibit 4.1 Final Form FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2025 Invivyd, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), is entitl |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 20, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 22, 2025 |
Exhibit 99.3 Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares WALTHAM, Mass., August 22, 2025 (GLOBE NEWSWIRE) – Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the closing of its previously announced underwritten public offering of 89,234,480 shares of its common stock, which includes the exercise in full |
|
| August 22, 2025 |
Invivyd Announces Proposed Public Offering of Common Stock Exhibit 99.1 Invivyd Announces Proposed Public Offering of Common Stock WALTHAM, Mass., August 20, 2025 (GLOBE NEWSWIRE) - Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Invivyd intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the share |
|
| August 20, 2025 |
SUBJECT TO COMPLETION, DATED AUGUST 20, 2025 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-267643 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| August 20, 2025 |
Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock FWP Issuer Free Writing Prospectus dated August 20, 2025 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration Statement No. |
|
| August 18, 2025 |
LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of William E. Duke, Jill Andersen, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact wi |
|
| August 18, 2025 |
Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of William E. Duke, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact with full power a |
|
| August 18, 2025 |
LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Jill Andersen, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact with full power and |
|
| August 18, 2025 |
LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of William E. Duke, Jill Andersen, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact wi |
|
| August 18, 2025 |
LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Exhibit 24.1 LIMITED POWER OF ATTORNEY FOR SECTION 16 AND RULE 144 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of William E. Duke, Jill Andersen, Katherine Fisher, Kiernan Decker, Stephen Nicolai, Steve Abrams and Amanda Brown, signing singly and each acting individually, as the undersigned’s true and lawful attorney‑in‑fact wi |
|
| August 14, 2025 |
EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights • PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year • Invivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus season • Announced alignment with U.S. FDA on |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, I |
|
| August 14, 2025 |
EX-99.2 Exhibit 99.2 Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19 • Alignment follows Type C meeting for VYD2311 as previously disclosed • BLA pathway for VYD2311 to be supported by a single, Phase 2/3 randomized, double-blind, placebo-controlled trial with a primary |
|
| August 14, 2025 |
EX-99.3 Exhibit 99.3 Corporate Deck August 2025 © 2025 Invivyd, Inc. Invivyd®, the Invivyd logo, Pemgarda® and the Ribbon logo are registered trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. 1 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private S |
|
| August 14, 2025 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| July 2, 2025 |
Invivyd and Leading Researchers Form SPEAR ( Exhibit 99.1 Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome - SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID - SPEA |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 26, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 26, 2025 |
Exhibit 99.1 Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection • Attractive safety profile demonstrated across all dosing cohorts and routes of administration (IV, SC, and IM); all reported adverse events (AEs) deemed unrelated or classified as mil |
|
| May 20, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 15, 2025 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 15, 2025 |
u Executive Summary u Commercial Update u R&D Overview u Clinical & Regulatory Finance Q&A 3 Exhibit 99.2 INVIVYD Q1 2025 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS May 15, 2025 © 2025 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Priv |
|
| May 15, 2025 |
Exhibit 99.1 Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights • PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force • PEMGARDA revenue re-acceleration observed in Q2 2025 to date • Invivyd continues to target near-term profitability (1H 2025) |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, |
|
| May 12, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 12, 2025 |
Exhibit 99.1 Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles • Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine could accelerate the pathway to functional eradication of measles • Measles (rubeola) |
|
| April 25, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 21, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 21, 2025 |
Exhibit 10.1 Certain Confidential Information in this document, marked by “[***]”, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COM |
|
| April 21, 2025 |
Exhibit 99.1 Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) – Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it has signed a $30 million term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Ba |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. ( |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 26, 2025 |
Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors Exhibit 99.1 Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) - Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. ( |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 20, 2025 |
Exhibit 10.2 INVIVYD, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 27, 2021 APPROVED BY THE STOCKHOLDERS: JULY 29, 2021 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve |
|
| March 20, 2025 |
Insider Trading Prevention Policy of the Registrant. Exhibit 19.1 InSIDER TRADING PREVENTION Policy 1.0 POLICY It is the policy of Invivyd, Inc. and its subsidiaries (“Invivyd”) to prohibit insider trading, i.e., the purchase or sale of a company’s securities by anyone who is aware of Material Non-Public Information (as defined below) about that company. Taking advantage of this privileged information is considered a breach of the individual’s fiduc |
|
| March 20, 2025 |
Employment Agreement by and between the Registrant and Timothy Lee, dated May 30, 2024. Exhibit 10.16 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Timothy Lee (“Executive”), this 30th day of May, 2024. Whereas, the Company desires to employ Executive in the role of Chief Commercial Officer of the Company, providing Executive with certain compensation and benefits in return for such employment s |
|
| March 20, 2025 |
Exhibit 10.15 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF JULIE GREEN This First Amendment to the Employment Agreement of Julie Green (the “Amendment”) is entered into this October 23, 2024 (the “Amendment Effective Date”), by and between JULIE GREEN (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and Executive have entered into that certain Employment Agreeme |
|
| March 20, 2025 |
Exhibit 99.1 Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights • Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million • 2024 year-end cash and cash equivalents of $69.3 million • Continu |
|
| March 20, 2025 |
Form of Indemnification Agreement with Executive Officers and Directors. Exhibit 10.4 INVIVYD, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , 20, and is between Invivyd, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporations or in certain other cap |
|
| March 5, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 5, 2025 |
Exhibit 99.1 Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1 • New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against LP.8.1 • Centers for Disease Control reports LP.8.1, XEC and KP.3.1.1 together constitute the majority of current national SARS-CoV-2 varian |
|
| February 24, 2025 |
Exhibit 99.1 FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients • FDA’s reasoning appears to center on a |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| February 12, 2025 |
EX-99 2 exhibit99.txt Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abiga |
|
| February 3, 2025 |
Exhibit 99.2 Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population • Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administration • Phase 1/2 clinical data for VYD2311 to date are positive for bot |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 3, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 3, 2025 |
Exhibit 99.1 Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability • Preliminary Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 million • Preliminary Q4 2024 total operating costs and expenses of approximately $32 million, 55% reduction comp |
|
| January 27, 2025 |
Exhibit 99.1 Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients • Treatment immunobridging analysis, routinely updated for contemporary SARS-CoV-2 variants, compares pemivibart antiviral titers |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 27, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2025 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 10, 2025 |
Exhibit 99.1 invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC • New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™ (pemivibart) against XEC • Centers for Disease Control reports XEC and KP.3.1.1 (previously disclosed as susceptible to PEMGARDA) together constitute the majority of national |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 27, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 12, 2024 |
IVVD / Invivyd, Inc. / Polaris Venture Partners V, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d896430dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) INVIVYD, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) Lauren Crockett Polaris Partners One Marina Park Drive, 8th Floor Boston, MA 02210 (781) 290-0770 (Na |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 27, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 14, 2024 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| November 14, 2024 |
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights Exhibit 99.1 Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights • Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalents • Targets near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various operational efficiency |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIV |
|
| November 14, 2024 |
Exhibit 99.2 INVIVYD Q3 2024 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS November 14, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. |
|
| November 14, 2024 |
IVVD / Invivyd, Inc. / MAVERICK CAPITAL LTD - SC 13G/A Passive Investment SC 13G/A 1 d848877dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Invivyd, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00534A102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 14, 2024 |
IVVD / Invivyd, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-ivvd093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* INVIVYD, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| November 14, 2024 |
Exhibit 99.3 Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor • The New England Journal of Medicine (NEJM) Letter to the Editor outlines the novel, rapid immunobridging authorization pathway for PEMGARDA and provide |
|
| November 12, 2024 |
IVVD / Invivyd, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 INVIVYD INC COMMON STOCK Cusip #00534A102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00534A102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,317,347 Item 6: 0 Item 7: 7,320,982 Item 8: 0 Item 9: 7,320,9 |
|
| November 8, 2024 |
IVVD / Invivyd, Inc. / GV 2019, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2426694d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Invivyd, Inc. (f/k/a Adagio Therapeutics, Inc.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00534A102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires |
|
| October 29, 2024 |
Exhibit 99.1 Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability • Preliminary Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with approximately $107 million in cash and cash equivalents • Expects to finish 2024 with $65 million or more in cash and cash equivalents • Withdraws for |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 29, 2024 |
Exhibit 99.2 Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants • Following strong protection (84% relative risk reduction versus placebo) demonstrated through month 6 with pemivibart, CANOPY clinical |
|
| September 23, 2024 |
Exhibit 99.1 Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) • Independent evaluation of KP.3.1.1 and LB.1 variants shows in vitro pseudovirus neutralization potency of PEMGARDA in-line with prior variants tested • Proprietary, ongoing SARS-CoV-2 spike analyses demonstrate consistent str |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 23, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 6, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 6, 2024 |
EX-99.1 Exhibit 99.1 Corporate Overview September 2024 © 2024 Invivyd, Inc. Invivy , Pemgar , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Refo |
|
| September 4, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 4, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 4, 2024 |
Exhibit 99.1 Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™ WALTHAM, Mass., September 4, 2024 – Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced dosing of the first participants i |
|
| September 3, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 3, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 3, 2024 |
Exhibit 99.1 Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest • New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDATM (pemivibart) against KP.3.1.1, LB.1, and other SARS-CoV-2 variants tested • Center for Disease Control reports KP.3.1.1 is the |
|
| August 27, 2024 |
Exhibit 99.2 INVIVYD CANOPY DATA UPDATE August 27, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation |
|
| August 27, 2024 |
Exhibit 99.1 Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial • In all-comer cohort of immunocompetent individuals at risk of contracting symptomatic COVID-19 in their everyday social interactions, participants receiving pemivibart experienced a 1.9% ra |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 14, 2024 |
Separation Agreement by and between the Company and David Hering, dated May 3, 2024. Exhibit 10.3 SEPARATION AGREEMENT April 19, 2024, as modified on May 3, 2024 David Hering [***] [***] Re: Separation Agreement Dear Dave: This letter sets forth the substance of the separation agreement (the “Agreement”) which Invivyd, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your employment is ending pursuant to Section 3(d) of your Employment A |
|
| August 14, 2024 |
Employment Agreement by and between the Company and Timothy Lee, dated May 30, 2024. Exhibit 10.1 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Timothy Lee (“Executive”), this 30th day of May, 2024. Whereas, the Company desires to employ Executive in the role of Chief Commercial Officer of the Company, providing Executive with certain compensation and benefits in return for such employment se |
|
| August 14, 2024 |
Separation Agreement by and between the Company and Jeremy Gowler, dated May 31, 2024. Exhibit 10.4 SEPARATION AGREEMENT May 31, 2024 Jeremy Gowler [***] [***] Re: Separation Agreement Dear Jeremy: This letter sets forth the substance of the separation agreement (the “Agreement”) which Invivyd, Inc. (the “Company”) is offering to you to aid in your employment transition. 1. Separation. Your last day of work with the Company and your employment termination date will be June 29, 2024 |
|
| August 14, 2024 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, I |
|
| August 14, 2024 |
Exhibit 99.1 INVIVYD REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS • PEMGARDA™ launched commercially in Q2 2024 with $2.3 million of net product revenue • Notable acceleration of commercial results in early Q3 2024, with the anticipated peak fall/winter respiratory virus season approaching • New commercial leadership with Chief Commercial Officer, Tim Lee, an experie |
|
| August 14, 2024 |
Exhibit 99.2 INVIVYD Q2 2024 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS August 14, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. P |
|
| June 14, 2024 |
Exhibit 99.1 Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants • Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses • Invivyd’s new |
|
| June 14, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 31, 2024 |
Exhibit 99.2 Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies • Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential eme |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 31, 2024 |
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer Exhibit 99.1 Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer • Mr. Lee joins Invivyd with a history of high-quality commercial execution at Alexion, Biohaven and Amylyx • Appointment intended to accelerate the addition of commercial capabilities associated with orphan medicines to the ongoing PEMGARDA™ commercial launch • William Duke, Jr., Chief Financial Officer, app |
|
| May 22, 2024 |
Invivyd Elects Two New Independent Members to its Board of Directors Exhibit 99.1 Invivyd Elects Two New Independent Members to its Board of Directors WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) – Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that two new independent directors, Dr. Srishti Gupta and Kevin F. McLaughlin, were elected to its Board of Directors at th |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
Exhibit 99.2 INVIVYD Q1 2024 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS May 9, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Priva |
|
| May 9, 2024 |
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights Exhibit 99.1 Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights • Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents with moderate-to-severe immune compromise • Reported interim exploratory COVID-19 clinical event data from CANOPY Phase 3 clinical trial of VYD222 • Received product-specific reimbursement co |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, INC. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(3) Proposed Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, $0.00 |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 7, 2024 |
Exhibit 99.1 Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback • Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior successful COVID-19 treatment clinical trial “STAMP” conducted with prototype antibody adintrevimab • Com |
|
| April 18, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. ( |
|
| April 18, 2024 |
INVIVYD, INC. 1601 Trapelo Road, Suite 178 Waltham, MA 02451 INVIVYD, INC. 1601 Trapelo Road, Suite 178 Waltham, MA 02451 April 18, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Re: Invivyd, Inc. Registration Statement on Form S-3 Filed February 9, 2024 File No. 333-276986 Request for Acceleration of Effective Date To Whom It May Co |
|
| April 12, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF JEREMY GOWLER This FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF JEREMY GOWLER (the “Amendment”) is entered into this April 11, 2024 (the “Amendment Effective Date”), by and between JEREMY GOWLER (the “Executive”) and INVIVYD, INC. (the “Company”). RECITALS WHEREAS, the Company and Executive have entered into that certain Employment Agre |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 11, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 12, 2024 |
Invivyd Announces CEO Transition Jeremy Gowler appointed Interim CEO Exhibit 99.1 Invivyd Announces CEO Transition Jeremy Gowler appointed Interim CEO WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Executive Officer (CEO), effecti |
|
| April 4, 2024 |
Exhibit 99.2 PEMGARDA LAUNCH UPDATE April 4, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 4, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 4, 2024 |
Exhibit 99.1 Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million • PEMGARDA now commercially available in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise • Based on anticipated net product revenue and continued optimization of opera |
|
| March 28, 2024 |
Exhibit 10.2 INVIVYD, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 27, 2021 APPROVED BY THE STOCKHOLDERS: JULY 29, 2021 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve |
|
| March 28, 2024 |
Form of Indemnification Agreement with Executive Officers and Directors. Exhibit 10.4 INVIVYD, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , 20, and is between Invivyd, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corporations or in certain other cap |
|
| March 28, 2024 |
Employment Agreement by and between the Registrant and Robert Allen, dated March 14, 2023. Exhibit 10.12 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Robert Allen (“Executive”), this 14th day of March, 2023. Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services, an |
|
| March 28, 2024 |
Employment Agreement by and between the Registrant and Julie Green, dated January 24, 2024. Exhibit 10.14 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Julie Green (“Executive”), this 24th day of January, 2024. Whereas, the Company and the Executive have entered into that certain Offer Letter dated April 14, 2022 (the “Offer Letter”), pursuant to which Executive has provided services to the Company |
|
| March 28, 2024 |
Exhibit 10.10 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF PETER SCHMIDT This First Amendment to the Employment Agreement of Peter Schmidt (the “Amendment”) is entered into this 6th day of December 2022 (the “Amendment Effective Date”), by and between Peter Schmidt (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and the Executive have entered into that certain |
|
| March 28, 2024 |
Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CONFIDENTIAL AMENDMENT NO. 2 TO THE CELL LINE LICENSE AGREEMENT THIS AMENDMENT NO. 2 TO THE CELL LINE LICENSE AGREEMENT (this “Amendment No. 2”), effective as of March 13, 2024 |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. ( |
|
| March 28, 2024 |
Employment Agreement by and between the Registrant and Peter Schmidt, dated November 9, 2020. Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Adagio Therapeutics, Inc., a Delaware corporation (the “Company”), and Peter Schmidt (the “Executive”) and is effective as of November 9, 2020 (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all r |
|
| March 28, 2024 |
Description of the Registrant’s Common Stock. Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Invivyd, Inc. (the “Company”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is the Company’s common |
|
| March 28, 2024 |
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights Exhibit 99.1 Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights • Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise • PEMGARDA product availability in the U.S. anticipated imminently • PEMGARDA |
|
| March 28, 2024 |
Employment Agreement by and between the Registrant and Stacy Price, dated February 3, 2023. Exhibit 10.11 Employment AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Stacy Price (“Executive”), this 3rd day of February, 2023. Whereas, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services, a |
|
| March 28, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 28, 2024 |
Incentive Compensation Recovery Policy of the Registrant. Exhibit 97.1 Incentive Compensation Recovery Policy 1.0 INTRODUCTION 1.1 Invivyd, Inc. (the “Company”) is committed to conducting business in accordance with the highest ethical and legal standards, and the Board of Directors of the Company (the “Board”) believes that a culture that emphasizes integrity and accountability is in the best interests of the Company and its stockholders and essential t |
|
| March 25, 2024 |
Exhibit 99.3 PEMGARDA FDA EMERGENCY USE AUTHORIZATION March 22, 2024 © 2024 Invivyd, Inc. Invivyd , Pemgarda , and the Ribbon logos are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securitie |
|
| March 25, 2024 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 22, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| March 25, 2024 |
Exhibit 99.1 Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 • PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise • Emergency use authorization based on positive immunobridging data and on safety data from the CANOPY clin |
|
| March 25, 2024 |
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial Exhibit 99.2 Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial • Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or review, but may be hypothesis generating for future Invivyd discovery and development work • Today’s update on Day 67 and Day 90 event rates is the first of two planned public updates on s |
|
| February 23, 2024 |
United States securities and exchange commission logo February 23, 2024 David Hering Chief Executive Officer Invivyd, Inc. |
|
| February 14, 2024 |
EX-99.A 2 d784351dex99a.htm EX-99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary Shares of Invivyd, Inc., dated as of February 14, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the |
|
| February 14, 2024 |
EX-99.B 3 d784351dex99b.htm EX-99.B EXHIBIT B Power of Attorney KNOW ALL MEN BY THESE PRESENTS, that I, Lee S. Ainslie III, hereby make, constitute and appoint Trevor Wiessmann as my agent and attorney-in-fact for the purpose of executing (i) in my personal capacity or (ii) in my capacity as manager or other officer or representative of Maverick Capital Management, LLC, Maverick Capital, Ltd. or a |
|
| February 14, 2024 |
ADGI / Adagio Therapeutics Inc / MAVERICK CAPITAL LTD - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Invivyd, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00534A102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 12, 2024 |
ADGI / Adagio Therapeutics Inc / Deep Track Capital, LP Passive Investment SC 13G 1 deeptrack-ivvd020224.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INVIVYD, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) February 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| February 9, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registrati |
|
| February 9, 2024 |
ADGI / Adagio Therapeutics Inc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.4 INVIVYD INC COMMON STOCK Cusip #00534A102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00534A102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,411,908 Item 6: 0 Item 7: 8,411,969 Item 8: 0 Item 9: 8,411,9 |
|
| February 9, 2024 |
As filed with the Securities and Exchange Commission on February 9, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 5, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 9, 2024 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 238) F-2 Consolidated Balance Sheets F-3 Consolidated Statements of Operations and Comprehensive Loss F-4 Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) F-5 Consolidated Statements of Cash Flows F-7 Notes to Consolidated Financial |
|
| January 22, 2024 |
ADGI / Adagio Therapeutics Inc / Adimab, LLC - SC 13D/A Activist Investment SC 13D/A 1 d615807dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Invivyd, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 00534A102 (CUSIP Number) Philip Chase 7 Lucent Drive Lebanon, NH 03766 (603) 643-7110 (Name, Address and Teleph |
|
| January 8, 2024 |
Exhibit 99.1 CORPORATE OVERVIEW January 8, 2024 © 2024 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. S |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 3, 2024 |
Exhibit 99.1 Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents • EUA submission is based on positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial and ongoing in vitro neutralization activity against relevant SARS-CoV-2 variants • VYD222 demonstrates c |
|
| January 3, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2024 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 22, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 22, 2023 |
EX-10.1 Exhibit 10.1 Execution Version Invivyd, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement December 22, 2023 Cantor Fitzgerald & Co. 110 East 59th Street New York, NY 10022 Ladies and Gentlemen: Invivyd, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as f |
|
| December 22, 2023 |
Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of such offering is $75,000,000. |
|
| December 22, 2023 |
Up to $75,000,000 Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-267643 PROSPECTUS SUPPLEMENT (To Prospectus dated October 5, 2022) Up to $75,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor, relating to shares of our common stock, par value $0.0001 per share, offered by this prosp |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 18, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| December 18, 2023 |
Exhibit 99.1 Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 • VYD222 produced high serum virus neutralizing antibody titer levels in immunocompromised participants • Data supportive of an immunobridging approach to the EVADE study of adintrevimab • Overall favorable safety and tolerability profile of |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 9, 2023 |
Exhibit 99.2 INVIVYD Q3 2023 FINANCIAL RESULTS & BUSINESS HIGHLIGHTS November 9, 2023 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Secur |
|
| November 9, 2023 |
Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FINAL [***] AMENDMENT NUMBER TWO TO THE COLLABORATION AGREEMENT This Amendment Number Two (this “Amendment”), dated September 19, 2023 (the “Amendment Two Effective Date”), amend |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, INC. |
|
| November 9, 2023 |
Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AGREEMENT SECOND AMENDED AND RESTATED COMMERCIAL MANUFACTURING SERVICES AGREEMENT THIS SECOND AMENDED AND RESTATED C |
|
| November 9, 2023 |
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights Exhibit 99.1 Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights • Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19 • Company expects to have initial CANOPY primary endpoint data by late 2023 or early Q1 2024 • Company aims to submit an application for Emergency Use Authorization (EUA) in t |
|
| September 11, 2023 |
Exhibit 99.1 CORPORATE OVERVIEW September 2023 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. St |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 11, 2023 |
ADGI / Adagio Therapeutics Inc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.3 INVIVYD INC COMMON STOCK Cusip #00534A102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00534A102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,573,722 Item 6: 0 Item 7: 8,573,782 Item 8: 0 Item 9: 8,573,782 Item 11: 7.811% Ite |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 5, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 5, 2023 |
INVIVYD APPOINTS WILLIAM DUKE AS CHIEF FINANCIAL OFFICER EX-99.1 Exhibit 99.1 INVIVYD APPOINTS WILLIAM DUKE AS CHIEF FINANCIAL OFFICER WALTHAM, Mass., September 5, 2023 (GLOBE NEWSWIRE) – Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of William Duke as Chief Financial Officer. Mr. Duke will lead Invivyd’s financial st |
|
| September 5, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and William Duke (“Executive”), this 19th day of July, 2023. WHEREAS, the Company desires for Executive to provide services to the Company, and wishes to provide Executive with certain compensation and benefits in return for such employment services, and |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR/ 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, INC. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| August 10, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF DAVID HERING This First Amendment to the Employment Agreement of David Hering (the “First Amendment”) is entered into this June 15, 2023 (the “Effective Date”), by and between David Hering (the “Executive”) and Invivyd, Inc. (the “Company”). Recitals WHEREAS, the Company and the Executive have entered into that certain Employment Agreemen |
|
| August 10, 2023 |
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights • Reported positive initial Phase 1 VYD222 clinical trial data, including favorable safety data and robust serum neutralizing titers from all three dose levels tested • Plans to pursue rapid initiation of a 750-participant pivotal clinical trial of VYD222 (CANOPY) that will utilize Day 28 serum neutr |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| July 27, 2023 |
INVIVYD ANNOUNCES APPOINTMENT OF SARA COTTER TO BOARD OF DIRECTORS Exhibit 99.1 INVIVYD ANNOUNCES APPOINTMENT OF SARA COTTER TO BOARD OF DIRECTORS WALTHAM, Mass., JULY 27, 2023 — Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced the appointment of Sara Cotter to its board of directors. Ms. Cotter brings extensive leadership experience spanning hea |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 29, 2023 |
EX-99.1 Exhibit 99.1 Corporate Overview June 2023 © 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 25, 2023 |
Exhibit 3.2 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF INVIVYD, INC. (A DELAWARE CORPORATION) The Amended and Restated Bylaws (the “Bylaws”) of Invivyd, Inc., a Delaware corporation, are hereby amended as follows, effective as of May 23rd, 2023. 1. Section 5(d) of Article III of the Bylaws is hereby amended and restated in its entirety to read as follows: “Notwithstanding anything in Se |
|
| May 25, 2023 |
Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INVIVYD, INC. Invivyd, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: Article V, Section B, Subsections 2 and 3 of the Amended and Restated Certificate of Incorporation of the Corporation (as |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40703 INVIVYD, INC. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 11, 2023 |
Exhibit 10.2 CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (this “Agreement”), effective as of February 4, 2023, (“Effective Date”) is between INVIVYD, Inc. a Delaware corporation having a place of business at 1601 Trapelo Road, Suite 178, Waltham, MA 02451, and its successors or assignees (“Invivyd” or the “Company”) and RDBio Consulting LLC, a Pennsylvania Limited Liability Co |
|
| May 11, 2023 |
EX-99.1 Exhibit 99.1 Invivyd Reports First Quarter 2023 Financial Results and Business Highlights Completed dosing of the Phase 1 clinical trial of VYD222, a broadly neutralizing monoclonal antibody (mAb) candidate being developed to protect immunocompromised people from COVID-19 Initial data readouts from Phase 1 VYD222 clinical trial planned for Q2 with additional clinical readouts from the VYD2 |
|
| May 11, 2023 |
Exhibit 10.3 Invivyd, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Invivyd, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service. |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2023 Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-40703 85-1403134 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 2, 2023 |
EX-99.1 Exhibit 99.1 Corporate Overview May 2023 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. (Exac |
|
| April 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
